1. Phylogeny:  
   TNK1, formally known as Non-receptor tyrosine‑protein kinase TNK1 (gene TNK1, Uniprot ID Q13470), is a member of the Activated Cdc42‑associated kinase (ACK) family within the large superfamily of non‑receptor tyrosine kinases (NRTKs) (chan2021tnk1isa pages 1-2). In humans, the ACK family is represented by only two kinases, TNK1 and its paralog TNK2 (also known as ACK1), and these kinases share a set of conserved catalytic and regulatory features that distinguish them from receptor tyrosine kinases (azevedo2019nonreceptortyrosinekinases pages 1-3). Phylogenetic classification studies based on kinase domain sequence conservation and domain organization place TNK1 in an evolutionarily ancient clade that has been maintained across vertebrate species, suggesting that its functions in regulating intracellular signaling—especially those governing cell proliferation and survival—are critical and conserved (bhanumathy2021proteintyrosinekinases pages 1-2). Additionally, comparative analyses reveal that the unique possession of a ubiquitin‑associated (UBA) domain in the C‑terminal region of TNK1 is a relatively uncommon feature among tyrosine kinases, further highlighting its specialized role in ubiquitin‑dependent processes (chan2021tnk1isa pages 1-2). Orthologs of TNK1 are identifiable in several metazoan lineages, underscoring its evolutionary conservation and reinforcing its significance as part of a core set of regulatory proteins within the eukaryotic kinome (azevedo2019nonreceptortyrosinekinases pages 1-3).
2. Reaction Catalyzed:  
   The catalytic function of TNK1 centers on the transfer of a phosphate group from adenosine triphosphate (ATP) to tyrosine residues on substrate proteins. In its canonical reaction, TNK1 utilizes ATP and a protein substrate containing an accessible tyrosine residue to generate adenosine diphosphate (ADP), a phosphorylated protein (protein‑tyrosine‑phosphate), and a proton (H⁺) as products (chan2021tnk1isa pages 8-10, blouin2011catalyticspecificityof pages 1-2). This phosphotransfer reaction is essential for modulating signaling cascades, as the phosphorylation of tyrosine residues serves as a molecular switch that alters the conformation, interaction capabilities, and activity of target proteins (chan2021tnk1isa pages 8-10).
3. Cofactor Requirements:  
   Similar to most protein kinases, the enzymatic activity of TNK1 is dependent on the presence of divalent cations, with magnesium (Mg²⁺) serving as the primary cofactor. Mg²⁺ stabilizes the binding of ATP to the kinase domain and facilitates the proper orientation of the phosphate groups for efficient transfer to the substrate (bhanumathy2021proteintyrosinekinases pages 1-2, blouin2011catalyticspecificityof pages 1-2). Although manganese (Mn²⁺) can occasionally substitute in vitro, Mg²⁺ remains the physiologically relevant cofactor for TNK1-mediated phosphorylation reactions.
4. Substrate Specificity:  
   Determination of TNK1 substrate specificity has been approached through both peptide substrate profiling and phosphoproteomic analyses. In vitro studies using a panel of synthetic peptides indicate that TNK1 preferentially phosphorylates substrates with a composition resembling polyGAT sequences, showing higher catalytic activity (relative activity ~15.2) compared to polyGT peptides (relative activity ~9.3), while peptides derived from regions of CDK1, IRS1, and JAK1 exhibit significantly lower phosphorylation levels (relative activities of ~2.4, ~1.6, and ~1.2, respectively) (blouin2011catalyticspecificityof pages 3-5). These data imply that TNK1 prefers substrate motifs that contain specific amino acid environments surrounding the target tyrosine residue, although a definitive consensus sequence has yet to be fully established. Additionally, cellular studies have identified that TNK1 phosphorylates physiologically relevant substrates such as STAT3 (notably at Y705) and phospholipase C‑γ (at Y783), thereby linking its activity to signaling pathways associated with cell proliferation and survival (chan2021tnk1isa pages 8-10). Collectively, these findings underscore a substrate specificity profile for TNK1 that is characteristic of tyrosine kinases, with a measurable preference for particular peptide motifs that likely contribute to its biological function.
5. Structure:  
   TNK1 exhibits a modular architecture that includes multiple distinct domains contributing to its catalytic function and regulatory interactions. Predominantly, TNK1 comprises a central kinase domain that encompasses the classic bilobal structure seen in most protein kinases; this domain contains the N‑terminal lobe, which is primarily composed of β‑sheets and the ATP‑binding pocket, and the larger C‑terminal lobe, which is primarily α‑helical and houses the activation loop (chan2021tnk1isa pages 8-10, hoare2009functionalcharacterizationof pages 7-8). Within the activation loop, autophosphorylation sites, notably tyrosine residues Y277 and Y287, have been identified as critical for achieving full enzymatic activity (hoare2009functionalcharacterizationof pages 7-8). Adjacent to the kinase domain, TNK1 features a proline‑rich domain that contains critical phosphorylation sites—such as serine 502—which mediate interactions with regulatory proteins, including members of the 14‑3‑3 family (chan2021tnk1isa pages 2-3, chan2021tnk1isa pages 3-5). The most unique structural feature of TNK1 is its C‑terminal ubiquitin‑associated (UBA) domain. Structural studies employing fusion crystallization approaches have revealed that the TNK1 UBA domain adopts a five‑helix bundle fold that is distinct from many conventional UBA domains observed in other proteins (nawarathnage2023fusioncrystallizationreveals pages 30-35). This UBA domain is responsible for high‑affinity binding to polyubiquitin chains, a property that is critical for the regulation of TNK1 stability and localization. Although an experimentally determined full‑length crystal structure of TNK1 is not available, integrative models based on homology and domain‑specific crystallographic studies provide detailed insights into its 3D structural organization and underscore the interplay between its catalytic and regulatory regions (chan2021tnk1isa pages 14-15, nawarathnage2023fusioncrystallizationreveals pages 30-35).
6. Regulation:  
   TNK1 activity is regulated by a combination of post‑translational modifications and protein‑protein interactions that are central to its role in modulating intracellular signaling. Autophosphorylation events within the kinase domain—specifically at tyrosine residues Y277 and Y287—are indispensable for full catalytic activation, serving as markers of active conformation (hoare2009functionalcharacterizationof pages 7-8). In addition, TNK1 is subject to phosphorylation by external kinases; for instance, phosphorylation at serine 502 within its proline‑rich domain is mediated by kinases such as MARK, and this modification enhances the binding affinity for 14‑3‑3 adaptor proteins (chan2021tnk1isa pages 3-5). The binding of 14‑3‑3 proteins to phosphorylated TNK1 acts as an inhibitory mechanism by sequestering TNK1 in the cytosol and preventing its aggregation into ubiquitin‑rich clusters (chan2021tnk1isa pages 1-2, chan2021tnk1isa pages 14-14). When released from 14‑3‑3 binding, TNK1 can translocate into punctate cellular structures where ubiquitin interaction via its UBA domain further promotes its activation (chan2021tnk1isa pages 16-17, nawarathnage2023fusioncrystallizationreveals pages 30-35). Such spatial regulation is critical, as it ensures that TNK1 activity is precisely controlled in response to cellular signals and stress, thereby maintaining appropriate levels of downstream phosphorylation. The interplay between autophosphorylation, kinase‑mediated phosphorylation by upstream kinases, and the binding of regulatory proteins exemplifies a complex regulatory network that modulates both the activity and localization of TNK1.
7. Function:  
   TNK1 serves multiple roles in cellular signaling networks that have significant implications for cell proliferation, survival, and immune responses. Functionally, TNK1 is involved in the negative regulation of cell growth, a property that underpins its classification as a tumor suppressor in certain contexts (hoare2009functionalcharacterizationof pages 7-8). It achieves this, in part, by acting as a negative regulator of the Ras‑MAPK signaling pathway; through its catalytic activity, TNK1 can phosphorylate substrates that attenuate Ras activation and thereby suppress downstream mitogenic signals (chan2021tnk1isa pages 1-2). TNK1 expression is developmentally regulated, with broad expression observed in fetal tissues and a more restricted pattern in adult tissues, particularly within cells of the lymphohematopoietic system (chan2021tnk1isa pages 2-3). In addition to its role in cell growth regulation, TNK1 has been identified as a novel antiviral host factor. Studies in hepatic cell models have demonstrated that overexpression of TNK1 enhances interferon (IFN) signaling—specifically by promoting serine phosphorylation of STAT1—which in turn modulates the expression of interferon‑stimulated genes (ISGs) that are critical for antiviral defense (ooi2014novelantiviralhost pages 1-2, ooi2014novelantiviralhost pages 2-3). Thus, TNK1 functions at the intersection of growth control and immune regulation, integrating signals from diverse pathways to modulate both cellular proliferation and antiviral responses. This dual functionality is further underscored by studies showing that dysregulation of TNK1 can contribute to aberrant cell survival, as evidenced by its involvement in growth factor‑independent proliferation in certain hematological contexts (siveen2018roleofnon pages 17-18).
8. Other Comments:  
   Recent efforts to modulate TNK1 activity for therapeutic benefit have led to the identification of small‑molecule inhibitors such as TP‑5801, which has shown nanomolar potency in preventing TNK1‑driven cellular transformation and in reducing tumor burden in preclinical models (chan2021tnk1isa pages 10-12, chan2021tnk1isa pages 15-16). In addition to chemical inhibitors, genetic studies have highlighted the potential clinical significance of TNK1 polymorphisms; for example, the rs11867353 variant in the TNK1 gene has been associated with an increased risk of Alzheimer’s disease, suggesting that TNK1 may also play a role in the pathogenesis of neurodegenerative disorders (zeman2021polymorphismrs11867353of pages 1-2, zeman2021polymorphismrs11867353of pages 9-9). Furthermore, the unique combination of tumor suppressor and growth inhibitory functions attributed to TNK1 is complemented by its ability to modulate phospholipid signal transduction, emphasizing its broad relevance in multiple signaling contexts (chan2021tnk1isa pages 1-2, siveen2018roleofnon pages 2-4). Although detailed consensus motifs for substrate recognition remain to be defined, available peptide profiling data provide a foundational basis for further exploration of TNK1’s substrate preferences, which may facilitate the development of more selective inhibitory compounds in the future (blouin2011catalyticspecificityof pages 3-5). Overall, TNK1 is emerging as a multifaceted kinase with implications in oncogenesis, immune regulation, and neurodegeneration, warranting extensive further research to fully elucidate its regulatory mechanisms and therapeutic potential.
9. References:
10. Chan, T., Egbert, C. M., Maxson, J. E., Siddiqui, A., Larsen, L., Kohler, K., et al. “TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth.” Nature Communications, Sep 2021. doi:10.1038/s41467-021-25622-3 (chan2021tnk1isa pages 1-2, 2-3, 8-10, 10-12, 13-14, 14-14, 15-16, 16-17).
11. Hoare, S., et al. “Functional characterization of the murine TNK1 promoter.” Gene, 444:1-9, Sep 2009. doi:10.1016/j.gene.2009.05.010 (hoare2009functionalcharacterizationof pages 7-8).
12. Ooi, E. L., Chan, S. T., Cho, N. E., Wilkins, C., Woodward, J., Li, M., et al. “Novel antiviral host factor, TNK1, regulates IFN signaling through serine phosphorylation of STAT1.” Proceedings of the National Academy of Sciences, 111:1909-1914, Jan 2014. doi:10.1073/pnas.1314268111 (ooi2014novelantiviralhost pages 1-2, 2-3, 3-3, 4-4, 4-5, 5-5, 5-6).
13. Azevedo, A., Silva, S., and Rueff, J. “Non-receptor tyrosine kinases role and significance in hematological malignancies.” In Tyrosine Kinases as Druggable Targets in Cancer, Sep 2019. doi:10.5772/intechopen.84873 (azevedo2019nonreceptortyrosinekinases pages 1-3, 6-8).
14. Bhanumathy, K. K., Balagopal, A., Vizeacoumar, F. S., Vizeacoumar, F. J., Freywald, A., and Giambra, V. “Protein tyrosine kinases: their roles and their targeting in leukemia.” Cancers, 13:184, Jan 2021. doi:10.3390/cancers13020184 (bhanumathy2021proteintyrosinekinases pages 1-2, 2-4, 12-13).
15. Blouin, J., Roby, P., Arcand, M., Beaudet, L., and Lipari, F. “Catalytic specificity of human protein tyrosine kinases revealed by peptide substrate profiling.” Current Chemical Genomics, 5:115-121, Aug 2011. doi:10.2174/1875397301105010115 (blouin2011catalyticspecificityof pages 1-2, 2-3, 3-5).
16. Eshaq, A. M., Flanagan, T. W., Hassan, S. Y., Al Asheikh, S. A., Al-Amoudi, W. A., Santourlidis, S., et al. “Non-receptor tyrosine kinases: their structure and mechanistic role in tumor progression and resistance.” Cancers, Aug 2024. doi:10.3390/cancers16152754 (eshaq2024nonreceptortyrosinekinases pages 12-14, 2-4, 14-16, 20-21, 21-23, 4-5, 7-9).
17. Nawarathnage, S., Tseng, Y. J., Soleimani, S., Smith, T., Pedroza Romo, M. J., Abiodun, W. O., et al. “Fusion crystallization reveals the behavior of both the 1TEL crystallization chaperone and the TNK1 UBA domain.” BioRxiv, Jun 2023. doi:10.1101/2023.06.14.544429 (nawarathnage2023fusioncrystallizationreveals pages 30-35, 18-21).
18. Zeman, T., Balcar, V. J., Cahová, K., Janoutová, J., Janout, V., Lochman, J., and Šerý, O. “Polymorphism rs11867353 of tyrosine kinase non-receptor 1 (TNK1) gene is a novel genetic marker for Alzheimer’s disease.” Molecular Neurobiology, 58:996-1005, Oct 2021. doi:10.1007/s12035-020-02153-4 (zeman2021polymorphismrs11867353of pages 1-2, 7-9, 9-9).
19. Siveen, K. S., Prabhu, K. S., Achkar, I. W., Kuttikrishnan, S., Shyam, S., Khan, A. Q., et al. “Role of non receptor tyrosine kinases in hematological malignancies and its targeting by natural products.” Molecular Cancer, Feb 2018. doi:10.1186/s12943-018-0788-y (siveen2018roleofnon pages 2-4, 5-6, 6-8, 17-18, 17-17).

References

1. (chan2021tnk1isa pages 1-2): T. Chan, Christina M Egbert, Julia E. Maxson, A. Siddiqui, Logan Larsen, Kristina Kohler, E. Balasooriya, K. Pennington, T. Tsang, Madison Frey, E. Soderblom, H. Geng, M. Müschen, Tetyana V. Forostyan, Savannah Free, Gaelle Mercenne, C. Banks, J. Valdoz, Clifford J. Whatcott, J. Foulks, D. Bearss, T. O’hare, D. Huang, K. Christensen, J. Moody, S. Warner, J. Tyner, and J. Andersen. Tnk1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. Nature Communications, Sep 2021. URL: https://doi.org/10.1038/s41467-021-25622-3, doi:10.1038/s41467-021-25622-3. This article has 24 citations and is from a highest quality peer-reviewed journal.
2. (chan2021tnk1isa pages 10-12): T. Chan, Christina M Egbert, Julia E. Maxson, A. Siddiqui, Logan Larsen, Kristina Kohler, E. Balasooriya, K. Pennington, T. Tsang, Madison Frey, E. Soderblom, H. Geng, M. Müschen, Tetyana V. Forostyan, Savannah Free, Gaelle Mercenne, C. Banks, J. Valdoz, Clifford J. Whatcott, J. Foulks, D. Bearss, T. O’hare, D. Huang, K. Christensen, J. Moody, S. Warner, J. Tyner, and J. Andersen. Tnk1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. Nature Communications, Sep 2021. URL: https://doi.org/10.1038/s41467-021-25622-3, doi:10.1038/s41467-021-25622-3. This article has 24 citations and is from a highest quality peer-reviewed journal.
3. (chan2021tnk1isa pages 14-15): T. Chan, Christina M Egbert, Julia E. Maxson, A. Siddiqui, Logan Larsen, Kristina Kohler, E. Balasooriya, K. Pennington, T. Tsang, Madison Frey, E. Soderblom, H. Geng, M. Müschen, Tetyana V. Forostyan, Savannah Free, Gaelle Mercenne, C. Banks, J. Valdoz, Clifford J. Whatcott, J. Foulks, D. Bearss, T. O’hare, D. Huang, K. Christensen, J. Moody, S. Warner, J. Tyner, and J. Andersen. Tnk1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. Nature Communications, Sep 2021. URL: https://doi.org/10.1038/s41467-021-25622-3, doi:10.1038/s41467-021-25622-3. This article has 24 citations and is from a highest quality peer-reviewed journal.
4. (chan2021tnk1isa pages 15-16): T. Chan, Christina M Egbert, Julia E. Maxson, A. Siddiqui, Logan Larsen, Kristina Kohler, E. Balasooriya, K. Pennington, T. Tsang, Madison Frey, E. Soderblom, H. Geng, M. Müschen, Tetyana V. Forostyan, Savannah Free, Gaelle Mercenne, C. Banks, J. Valdoz, Clifford J. Whatcott, J. Foulks, D. Bearss, T. O’hare, D. Huang, K. Christensen, J. Moody, S. Warner, J. Tyner, and J. Andersen. Tnk1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. Nature Communications, Sep 2021. URL: https://doi.org/10.1038/s41467-021-25622-3, doi:10.1038/s41467-021-25622-3. This article has 24 citations and is from a highest quality peer-reviewed journal.
5. (chan2021tnk1isa pages 16-17): T. Chan, Christina M Egbert, Julia E. Maxson, A. Siddiqui, Logan Larsen, Kristina Kohler, E. Balasooriya, K. Pennington, T. Tsang, Madison Frey, E. Soderblom, H. Geng, M. Müschen, Tetyana V. Forostyan, Savannah Free, Gaelle Mercenne, C. Banks, J. Valdoz, Clifford J. Whatcott, J. Foulks, D. Bearss, T. O’hare, D. Huang, K. Christensen, J. Moody, S. Warner, J. Tyner, and J. Andersen. Tnk1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. Nature Communications, Sep 2021. URL: https://doi.org/10.1038/s41467-021-25622-3, doi:10.1038/s41467-021-25622-3. This article has 24 citations and is from a highest quality peer-reviewed journal.
6. (chan2021tnk1isa pages 2-3): T. Chan, Christina M Egbert, Julia E. Maxson, A. Siddiqui, Logan Larsen, Kristina Kohler, E. Balasooriya, K. Pennington, T. Tsang, Madison Frey, E. Soderblom, H. Geng, M. Müschen, Tetyana V. Forostyan, Savannah Free, Gaelle Mercenne, C. Banks, J. Valdoz, Clifford J. Whatcott, J. Foulks, D. Bearss, T. O’hare, D. Huang, K. Christensen, J. Moody, S. Warner, J. Tyner, and J. Andersen. Tnk1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. Nature Communications, Sep 2021. URL: https://doi.org/10.1038/s41467-021-25622-3, doi:10.1038/s41467-021-25622-3. This article has 24 citations and is from a highest quality peer-reviewed journal.
7. (chan2021tnk1isa pages 8-10): T. Chan, Christina M Egbert, Julia E. Maxson, A. Siddiqui, Logan Larsen, Kristina Kohler, E. Balasooriya, K. Pennington, T. Tsang, Madison Frey, E. Soderblom, H. Geng, M. Müschen, Tetyana V. Forostyan, Savannah Free, Gaelle Mercenne, C. Banks, J. Valdoz, Clifford J. Whatcott, J. Foulks, D. Bearss, T. O’hare, D. Huang, K. Christensen, J. Moody, S. Warner, J. Tyner, and J. Andersen. Tnk1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. Nature Communications, Sep 2021. URL: https://doi.org/10.1038/s41467-021-25622-3, doi:10.1038/s41467-021-25622-3. This article has 24 citations and is from a highest quality peer-reviewed journal.
8. (bhanumathy2021proteintyrosinekinases pages 1-2): Kalpana K. Bhanumathy, Amrutha Balagopal, Frederick S. Vizeacoumar, Franco J. Vizeacoumar, Andrew Freywald, and Vincenzo Giambra. Protein tyrosine kinases: their roles and their targeting in leukemia. Cancers, 13:184, Jan 2021. URL: https://doi.org/10.3390/cancers13020184, doi:10.3390/cancers13020184. This article has 75 citations and is from a peer-reviewed journal.
9. (chan2021tnk1isa pages 14-14): T. Chan, Christina M Egbert, Julia E. Maxson, A. Siddiqui, Logan Larsen, Kristina Kohler, E. Balasooriya, K. Pennington, T. Tsang, Madison Frey, E. Soderblom, H. Geng, M. Müschen, Tetyana V. Forostyan, Savannah Free, Gaelle Mercenne, C. Banks, J. Valdoz, Clifford J. Whatcott, J. Foulks, D. Bearss, T. O’hare, D. Huang, K. Christensen, J. Moody, S. Warner, J. Tyner, and J. Andersen. Tnk1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. Nature Communications, Sep 2021. URL: https://doi.org/10.1038/s41467-021-25622-3, doi:10.1038/s41467-021-25622-3. This article has 24 citations and is from a highest quality peer-reviewed journal.
10. (chan2021tnk1isa pages 3-5): T. Chan, Christina M Egbert, Julia E. Maxson, A. Siddiqui, Logan Larsen, Kristina Kohler, E. Balasooriya, K. Pennington, T. Tsang, Madison Frey, E. Soderblom, H. Geng, M. Müschen, Tetyana V. Forostyan, Savannah Free, Gaelle Mercenne, C. Banks, J. Valdoz, Clifford J. Whatcott, J. Foulks, D. Bearss, T. O’hare, D. Huang, K. Christensen, J. Moody, S. Warner, J. Tyner, and J. Andersen. Tnk1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. Nature Communications, Sep 2021. URL: https://doi.org/10.1038/s41467-021-25622-3, doi:10.1038/s41467-021-25622-3. This article has 24 citations and is from a highest quality peer-reviewed journal.
11. (eshaq2024nonreceptortyrosinekinases pages 12-14): Abdulaziz M. Eshaq, Thomas W Flanagan, Sofie Y. Hassan, Sara A. Al Asheikh, Waleed A. Al-Amoudi, S. Santourlidis, Sarah-Lilly Hassan, Maryam O Alamodi, M. Bendhack, M. Alamodi, Youssef Haikel, Mossad Megahed, and Mohamed Hassan. Non-receptor tyrosine kinases: their structure and mechanistic role in tumor progression and resistance. Cancers, Aug 2024. URL: https://doi.org/10.3390/cancers16152754, doi:10.3390/cancers16152754. This article has 6 citations and is from a peer-reviewed journal.
12. (nawarathnage2023fusioncrystallizationreveals pages 30-35): Supeshala Nawarathnage, Yi Jie Tseng, Sara Soleimani, Tobin Smith, Maria J Pedroza Romo, Wisdom Oshireku Abiodun, Christina M. Egbert, Deshan Madhusanka, Derick Bunn, Bridger Woods, Evan Tsubaki, Cameron Stewart, Seth Brown, Tzanko Doukov, Joshua L. Andersen, and James D. Moody. Fusion crystallization reveals the behavior of both the 1tel crystallization chaperone and the tnk1 uba domain. BioRxiv, Jun 2023. URL: https://doi.org/10.1101/2023.06.14.544429, doi:10.1101/2023.06.14.544429. This article has 2 citations.
13. (ooi2014novelantiviralhost pages 1-2): Ee Lyn Ooi, Stephanie T. Chan, Noell E. Cho, Courtney Wilkins, Jessica Woodward, Meng Li, Ushio Kikkawa, Timothy Tellinghuisen, Michael Gale, and Takeshi Saito. Novel antiviral host factor, tnk1, regulates ifn signaling through serine phosphorylation of stat1. Proceedings of the National Academy of Sciences, 111:1909-1914, Jan 2014. URL: https://doi.org/10.1073/pnas.1314268111, doi:10.1073/pnas.1314268111. This article has 47 citations.
14. (ooi2014novelantiviralhost pages 2-3): Ee Lyn Ooi, Stephanie T. Chan, Noell E. Cho, Courtney Wilkins, Jessica Woodward, Meng Li, Ushio Kikkawa, Timothy Tellinghuisen, Michael Gale, and Takeshi Saito. Novel antiviral host factor, tnk1, regulates ifn signaling through serine phosphorylation of stat1. Proceedings of the National Academy of Sciences, 111:1909-1914, Jan 2014. URL: https://doi.org/10.1073/pnas.1314268111, doi:10.1073/pnas.1314268111. This article has 47 citations.
15. (siveen2018roleofnon pages 17-18): Kodappully S. Siveen, Kirti S. Prabhu, Iman W. Achkar, Shilpa Kuttikrishnan, Sunitha Shyam, Abdul Q. Khan, Maysaloun Merhi, Said Dermime, and Shahab Uddin. Role of non receptor tyrosine kinases in hematological malignances and its targeting by natural products. Molecular Cancer, Feb 2018. URL: https://doi.org/10.1186/s12943-018-0788-y, doi:10.1186/s12943-018-0788-y. This article has 160 citations and is from a highest quality peer-reviewed journal.
16. (zeman2021polymorphismrs11867353of pages 1-2): Tomáš Zeman, Vladimir J. Balcar, Kamila Cahová, Jana Janoutová, Vladimír Janout, Jan Lochman, and Omar Šerý. Polymorphism rs11867353 of tyrosine kinase non-receptor 1 (tnk1) gene is a novel genetic marker for alzheimer’s disease. Molecular Neurobiology, 58:996-1005, Oct 2021. URL: https://doi.org/10.1007/s12035-020-02153-4, doi:10.1007/s12035-020-02153-4. This article has 6 citations and is from a peer-reviewed journal.
17. (zeman2021polymorphismrs11867353of pages 9-9): Tomáš Zeman, Vladimir J. Balcar, Kamila Cahová, Jana Janoutová, Vladimír Janout, Jan Lochman, and Omar Šerý. Polymorphism rs11867353 of tyrosine kinase non-receptor 1 (tnk1) gene is a novel genetic marker for alzheimer’s disease. Molecular Neurobiology, 58:996-1005, Oct 2021. URL: https://doi.org/10.1007/s12035-020-02153-4, doi:10.1007/s12035-020-02153-4. This article has 6 citations and is from a peer-reviewed journal.
18. (azevedo2019nonreceptortyrosinekinases pages 1-3): Ana Azevedo, Susana Silva, and José Rueff. Non-receptor tyrosine kinases role and significance in hematological malignancies. Tyrosine Kinases as Druggable Targets in Cancer, Sep 2019. URL: https://doi.org/10.5772/intechopen.84873, doi:10.5772/intechopen.84873. This article has 15 citations.
19. (blouin2011catalyticspecificityof pages 1-2): J. Blouin, P. Roby, M. Arcand, L. Beaudet, and F. Lipari. Catalytic specificity of human protein tyrosine kinases revealed by peptide substrate profiling. Current Chemical Genomics, 5:115-121, Aug 2011. URL: https://doi.org/10.2174/1875397301105010115, doi:10.2174/1875397301105010115. This article has 12 citations.
20. (blouin2011catalyticspecificityof pages 3-5): J. Blouin, P. Roby, M. Arcand, L. Beaudet, and F. Lipari. Catalytic specificity of human protein tyrosine kinases revealed by peptide substrate profiling. Current Chemical Genomics, 5:115-121, Aug 2011. URL: https://doi.org/10.2174/1875397301105010115, doi:10.2174/1875397301105010115. This article has 12 citations.
21. (hoare2009functionalcharacterizationof pages 7-8): Sarasija Hoare, Kishalay Hoare, Mary K. Reinhard, Tammy O. Flagg, and William Stratford May. Functional characterization of the murine tnk1 promoter. Gene, 444:1-9, Sep 2009. URL: https://doi.org/10.1016/j.gene.2009.05.010, doi:10.1016/j.gene.2009.05.010. This article has 11 citations and is from a peer-reviewed journal.
22. (siveen2018roleofnon pages 2-4): Kodappully S. Siveen, Kirti S. Prabhu, Iman W. Achkar, Shilpa Kuttikrishnan, Sunitha Shyam, Abdul Q. Khan, Maysaloun Merhi, Said Dermime, and Shahab Uddin. Role of non receptor tyrosine kinases in hematological malignances and its targeting by natural products. Molecular Cancer, Feb 2018. URL: https://doi.org/10.1186/s12943-018-0788-y, doi:10.1186/s12943-018-0788-y. This article has 160 citations and is from a highest quality peer-reviewed journal.